Comparative Efficacy and Safety of First-Line Immune Checkpoint Inhibitors Plus Chemotherapy with or Without Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Carcinoma.

Simple Summary: For patients with advanced non-squamous non-small cell lung cancer lacking EGFR or ALK mutations, initial treatment typically involves a combination of chemotherapy and immunotherapy. While adding the anti-angiogenic drug bevacizumab to chemotherapy has previously shown benefit, its...

Full description

Bibliographic Details

Published in:	Current Oncology Vol. 31; no. 3; pp. 173 - 191
Main Authors:	Chen, Ping, Wang, Mengchi, Peng, Siyan, Zhu, Honglin, Wang, Yanming, Wan, Zixuan, Yang, Xuan, Yu, Zhixin, Zhou, Yixin
Format:	Journal Article
Published:	MDPI Mar2026
Online Access:	View this record in EBSCOhost